Cantaloupes Recalled in Four States Due to Salmonella Risk
via HealthDayTUESDAY, April 21, 2026 — Health officials in some states are warning shoppers to avoid certain cantaloupes amid concerns they may carry Salmonella.
The recall, announced by the U.S. Food and Drug Administration (FDA), involves fruit produced by Ayco Farms Inc. and first pulled from shelves on March 24, Health.com reported.
In total, 8,302 cartons of cantaloupes are affected. The fruit was shipped to California, Florida, New York and Pennsylvania.
The cantaloupes were sold whole and packaged in food-safe plastic bags, then placed in cardboard cartons containing six to 12 melons each.
Several lot numbers are affected, the FDA said: GC26257, GC26270, GC26288, GC26289, GC26290, GC26294, GC26299, GC26301, GC26307, GC26308, GC26311, GC26312, GC26313, GC26318, GC26325, GC26326, GC26328, SCX2601, SCX2606, SCX2611, SCX2614, SCX2622, SCX2625, SCX2629, SCX2633, SGC2601, SGC2602 and SGC2607.
Salmonella can cause symptoms like diarrhea, fever and stomach cramps, and can be particularly dangerous for young kids, older adults and people with weak immune systems.
The FDA did not provide detailed instructions for consumers, but experts say the safest choice is to avoid eating the recalled cantaloupe, Health.com said.
Anyone who has purchased these should throw them away and disinfect any surfaces they may have touched to prevent possible contamination.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-04-22 02:09
Read more
- Novartis IgAN data in New England Journal of Medicine Show Fabhalta Slowed Kidney Function Decline by 49.3%
- Travere Therapeutics Announces Full FDA Approval of Filspari (sparsentan), the First and Only Approved Medicine for Focal Segmental Glomerulosclerosis (FSGS)
- Naloxone's OD-Reversing Powers Challenged By Today's Opioids, Tests Show
- AAD: Upadacitinib Safe, Effective for Nonsegmental Vitiligo
- New Weight Loss Pill, Foundayo, Gets Approval But FDA Seeks More Safety Data
- One in Four Use AI for Health Information
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions